Payment overview · 2025
General Payments
$34.77
2 reported records · 2 companies
Healthcare provider profile · identity verified
Brian Doyle Brown, M.D.
Allopathic & Osteopathic Physicians|Emergency Medicine · CORPUS CHRISTI, TX · NPI 1558638361
Verified facts
What the public records show
CMS Open Payments records show Brian Doyle Brown, M.D. received $34.77 in general payments during 2025 across 2 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 54.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.09 | 54.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.68 | 45.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $34.77 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 443 | 70 |
| Eliquis | Apixaban | 383 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 51 |
| Furosemide | Furosemide | 320 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 303 | 50 |
| Donepezil Hcl | Donepezil Hcl | 273 | 39 |
| Gabapentin | Gabapentin | 248 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 244 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 240 | 39 |
| Memantine Hcl | Memantine Hcl | 234 | 31 |
| Divalproex Sodium | Divalproex Sodium | 228 | 33 |
| Trazodone Hcl | Trazodone Hcl | 220 | 41 |
| Losartan Potassium | Losartan Potassium | 200 | 42 |
| Carvedilol | Carvedilol | 164 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 32 |
| Metformin Hcl | Metformin Hcl | 151 | 25 |
| Potassium Chloride | Potassium Chloride | 144 | 32 |
| Lactulose | Lactulose | 135 | 43 |
| Levetiracetam | Levetiracetam | 133 | 18 |
| Buspirone Hcl | Buspirone Hcl | 129 | 25 |
| Lisinopril | Lisinopril | 127 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 22 |
| Sertraline Hcl | Sertraline Hcl | 106 | 15 |
| Mirtazapine | Mirtazapine | 102 | 21 |
| Simvastatin | Simvastatin | 100 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 85 | 75 |
| Olanzapine | Olanzapine | 84 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 82 | 16 |
| Tramadol Hcl | Tramadol Hcl | 82 | 40 |
| Glipizide | Glipizide | 81 | suppressed |
| Lorazepam | Lorazepam | 80 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 21 |
| Alendronate Sodium | Alendronate Sodium | 77 | 11 |
| Alprazolam | Alprazolam | 74 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 73 | suppressed |
| Sucralfate | Sucralfate | 73 | 17 |
| Famotidine | Famotidine | 71 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 19 |
| Fenofibrate | Fenofibrate | 65 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 64 | 36 |
| Baclofen | Baclofen | 64 | suppressed |
| Jardiance | Empagliflozin | 64 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 55 | suppressed |
| Spironolactone | Spironolactone | 54 | 12 |
| Methylprednisolone | Methylprednisolone | 53 | 49 |
| Insulin Lispro | Insulin Lispro | 50 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 15 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Tradjenta | Linagliptin | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 36 |
| Finasteride | Finasteride | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | suppressed |
| Nifedipine Er | Nifedipine | 43 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Ondansetron Odt | Ondansetron | 42 | 38 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Meloxicam | Meloxicam | 39 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 14 |
| Digoxin | Digoxin | 36 | suppressed |
| Novolog | Insulin Aspart | 36 | suppressed |
| Prednisone | Prednisone | 36 | 18 |
| Latanoprost | Latanoprost | 35 | suppressed |
| Folic Acid | Folic Acid | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 31 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 25 |
| Levofloxacin | Levofloxacin | 31 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 14 |
| Azithromycin | Azithromycin | 28 | 23 |
| Ceftriaxone | Ceftriaxone Sodium | 28 | 25 |
| Lidocaine Hcl | Lidocaine Hcl | 28 | 22 |
| Phenytoin | Phenytoin | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 12 |
| Levemir | Insulin Detemir | 23 | suppressed |
| Humalog | Insulin Lispro | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 14 |
| Fiasp | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 13 |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Constulose | Lactulose | 14 | 11 |
| Enulose | Lactulose | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Omeprazole | Omeprazole | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | 11 |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34.77 · 2 records | Otsuka America Pharmaceutical, Inc. | REXULTI | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error